A scoping review of the problems and solutions associated with contamination in trials of complex interventions in mental health.
Complex interventions
Mental health
Randomised controlled trials
Treatment contamination
Journal
BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545
Informations de publication
Date de publication:
07 01 2019
07 01 2019
Historique:
received:
07
02
2018
accepted:
17
12
2018
entrez:
9
1
2019
pubmed:
9
1
2019
medline:
14
1
2020
Statut:
epublish
Résumé
In a randomised controlled trial, contamination is defined as the receipt of active intervention amongst participants in the control arm. This review assessed the processes leading to contamination, its typical quantity, methods used to mitigate it, and impact of use of cluster randomisation to prevent it on study findings in trials of complex interventions in mental health. This is a scoping review of trial design approaches and methods of study conduct to address contamination. Studies included were randomised controlled trials of complex interventions in mental health that described the process leading to, amount of, or solution used to counter contamination. The Medline, Embase, and PsycInfo databases were searched for trials published between 2000 and 2015. Risk of bias was assessed using the Jadad score and domains recommended by Cochrane plus some relevant to cluster randomised trials. Two hundred and thirty-four articles were included in the review. The main processes that led to contamination were health professionals delivering both active and comparator treatments and communication among clinicians and participants from the different trial arms. Twenty-three trials (10%) measured binary treatment receipt in the control arm with median 13% of participants found to be contaminated (IQR 5-33%). The most common design approach for dealing with contamination was the use of cluster randomisation (n = 93). In addition, many researchers used simple trial conduct methods to minimise contamination due to suspected contamination processes, such as organising for each clinician to provide only one treatment and separating trial arms spatially or temporally. There was little evidence for a relationship between cluster randomisation to avoid contamination and size of treatment effect estimate. There was some evidence of modest levels of treatment contamination with a large range, although a minority of studies reported the amount of contamination. A limitation was that many trials described the problem in little detail. Overall there is a need for greater measurement and reporting of treatment receipt in the control arm of trials. Researchers should be aware of trial conduct methods that can be used to minimise contamination without resorting to cluster randomisation.
Sections du résumé
BACKGROUND
In a randomised controlled trial, contamination is defined as the receipt of active intervention amongst participants in the control arm. This review assessed the processes leading to contamination, its typical quantity, methods used to mitigate it, and impact of use of cluster randomisation to prevent it on study findings in trials of complex interventions in mental health.
METHODS
This is a scoping review of trial design approaches and methods of study conduct to address contamination. Studies included were randomised controlled trials of complex interventions in mental health that described the process leading to, amount of, or solution used to counter contamination. The Medline, Embase, and PsycInfo databases were searched for trials published between 2000 and 2015. Risk of bias was assessed using the Jadad score and domains recommended by Cochrane plus some relevant to cluster randomised trials.
RESULTS
Two hundred and thirty-four articles were included in the review. The main processes that led to contamination were health professionals delivering both active and comparator treatments and communication among clinicians and participants from the different trial arms. Twenty-three trials (10%) measured binary treatment receipt in the control arm with median 13% of participants found to be contaminated (IQR 5-33%). The most common design approach for dealing with contamination was the use of cluster randomisation (n = 93). In addition, many researchers used simple trial conduct methods to minimise contamination due to suspected contamination processes, such as organising for each clinician to provide only one treatment and separating trial arms spatially or temporally. There was little evidence for a relationship between cluster randomisation to avoid contamination and size of treatment effect estimate.
CONCLUSION
There was some evidence of modest levels of treatment contamination with a large range, although a minority of studies reported the amount of contamination. A limitation was that many trials described the problem in little detail. Overall there is a need for greater measurement and reporting of treatment receipt in the control arm of trials. Researchers should be aware of trial conduct methods that can be used to minimise contamination without resorting to cluster randomisation.
Identifiants
pubmed: 30616508
doi: 10.1186/s12874-018-0646-z
pii: 10.1186/s12874-018-0646-z
pmc: PMC6323722
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Subventions
Organisme : Department of Health
ID : DRF-2014-07-002
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K006185/1
Pays : United Kingdom
Organisme : Research Trainees Coordinating Centre
ID : DRF-2014-07-002
Pays : International
Références
JAMA. 2009 Mar 25;301(12):1242-52
pubmed: 19318652
J Psychiatr Ment Health Nurs. 2005 Oct;12(5):556-64
pubmed: 16164506
Eur J Cancer. 1995 Nov;31A(12):1934-44
pubmed: 8562145
Aust Occup Ther J. 2014 Dec;61(6):424-36
pubmed: 25284162
Res Nurs Health. 2011 Feb;34(1):7-19
pubmed: 21243655
Psychol Med. 2007 Mar;37(3):363-72
pubmed: 17311685
J Occup Environ Med. 2000 Jan;42(1):47-56
pubmed: 10652688
Psychol Med. 2008 Feb;38(2):279-87
pubmed: 17803837
J Clin Epidemiol. 2008 Feb;61(2):160-168
pubmed: 18177789
J Am Acad Child Adolesc Psychiatry. 2006 Mar;45(3):314-321
pubmed: 16540816
Br J Psychiatry. 2004 Aug;185:163-8
pubmed: 15286069
Health Technol Assess. 2015 Nov;19(93):1-115, v-vi
pubmed: 26560448
J Natl Cancer Inst. 2004 Apr 7;96(7):529-38
pubmed: 15069115
Lancet Oncol. 2011 Aug;12(8):753-62
pubmed: 21741309
J Pediatr Psychol. 2013 Oct;38(9):944-53
pubmed: 23671058
J Consult Clin Psychol. 2011 Apr;79(2):261-5
pubmed: 21299274
Schizophr Bull. 2013 Nov;39(6):1242-51
pubmed: 24072808
BMJ. 2001 Feb 10;322(7282):355-7
pubmed: 11159665
Am J Prev Med. 1998 Oct;15(3):206-11
pubmed: 9791638
J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1041-1050
pubmed: 17667482
BMJ. 2003 Oct 4;327(7418):785-9
pubmed: 14525877
Stat Med. 1997 May 15;16(9):1017-29
pubmed: 9160496
J Gen Intern Med. 2005 Dec;20(12):1084-90
pubmed: 16423095
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
BMC Med Res Methodol. 2005 Mar 02;5:10
pubmed: 15743523
J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):422-31
pubmed: 18931624
Nurs Res. 2002 Jul-Aug;51(4):219-28
pubmed: 12131234
Arch Dis Child. 2004 Jun;89(6):519-25
pubmed: 15155394
Psychother Psychosom. 2010 Jun;79(4):217-26
pubmed: 20424499
Health Serv Res. 2013 Feb;48(1):150-74
pubmed: 22716199
Pain. 2008 Aug 15;138(1):29-40
pubmed: 18086516
Health Soc Care Community. 2013 Sep;21(5):545-53
pubmed: 23639030
Pain. 2011 Dec;152(12):2710-20
pubmed: 21920668
BMC Med Res Methodol. 2013 Mar 23;13:48
pubmed: 23522333
Thorax. 2007 Oct;62(10):898-903
pubmed: 17483139
J Consult Clin Psychol. 2001 Feb;69(1):33-40
pubmed: 11302275
J Consult Clin Psychol. 2001 Aug;69(4):604-13
pubmed: 11550727
Health Technol Assess. 2007 Oct;11(43):iii, ix-107
pubmed: 17935683
BJOG. 2005 Sep;112(9):1249-56
pubmed: 16101604
Br J Psychiatry. 2008 Dec;193(6):477-84
pubmed: 19043151
J Am Geriatr Soc. 2000 Apr;48(4):442-9
pubmed: 10798473
JAMA. 2013 Sep 18;310(11):1156-67
pubmed: 24045740
J Dent Res. 2009 Oct;88(10):933-7
pubmed: 19783802
BMJ. 2000 Sep 16;321(7262):694-6
pubmed: 10987780
Clin Rehabil. 2010 Apr;24(4):305-18
pubmed: 20360151
J Epidemiol Community Health. 2014 Jul;68(7):606-14
pubmed: 24489043
Stat Methods Med Res. 2005 Aug;14(4):369-95
pubmed: 16178138
J Am Geriatr Soc. 2005 May;53(5):803-10
pubmed: 15877555
Addiction. 2013 Mar;108(3):618-28
pubmed: 22994457
J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):569-77
pubmed: 17310937
J Am Acad Child Adolesc Psychiatry. 2005 Nov;44(11):1118-27
pubmed: 16239860
Br J Psychiatry. 2007 Nov;191:451-2
pubmed: 17978327
Psychooncology. 2003 Jun;12(4):357-74
pubmed: 12748973
Child Care Health Dev. 2004 Sep;30(5):413-27
pubmed: 15320919
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):208-15
pubmed: 22732470